How much revenue does Nuvalent make?

Nuvalent reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.

What companies are similar to Nuvalent?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Ipsen S.a. (IPN.PA), ImmunityBio, Inc. (IBRX), Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS), InventisBio Co., Limited (688382.SS).

Nuvalent, Inc. (NUVL) Stock

FinancialsShareholders

About Nuvalent, Inc.

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine ki...

At a glance

Nuvalent reported revenue of $0 for fiscal year 2025, and net income of -$425.38 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.